Compared with first-generation FLT3 inhibitor therapy, Gilteritinib can effectively inhibit multiple secondary resistance mutations, thereby overcoming resistance issues and more effectively improving the survival rate and response rate of AML patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.